BIOMEDevice San Jose is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BIOMEDigital 2020 Session Viewer

Welcome to the BIOMEDigital session viewer. Browse and sort the growing list of sessions by day or track. All sessions are shown in Eastern Time.

Proven Processes for High-Volume Ultra-Miniaturized Devices

Donna Bibber  (VP of Business Development, Isometric Micro Molding)

Location: Center Stage

Date: Wednesday, November 4

Time: 1:00pm - 2:00pm

Track: Center Stage

Vault Recording: TBD

This technical presentation debunks the myths and theories around design limitations of miniaturized devices. Perceived biases exist during design and CAD modelling that place limits on geometry, size, and feature size regarding high-volume medical and drug delivery miniaturized device designs such as:

  • High speed automated assemblies of 5-10 micron-positional accuracy
  • Biomimicry surface finishes that defines how and where fluid is attracted or repelled
  • 50:1 and higher aspect ratios
  • 002” (50 µm) wall thicknesses of both injection-molded and 3d printed parts
  • An injection molded part down to a fraction of a plastic pellet in size
  • 5-micron radii on needle, anchor, cannula, or sheath
  • 002” (50 µm) injection molded holes in a filter-like pattern


The outputs to high volume, miniaturized device designs are:

  1. Significant company value and intellectual property
  2. Platform products
  3. Individual, industry, and inter-company innovative product honors of both scientific and commercial prominence


With these rewards come risks and challenges that are rarely extrapolated by previous learnings of conventional or macro methods of manufacturing. This technical presentation explores high volume proven processes of scaling multi-cavity tooling to multiple component assemblies, reducing to practice the basic principles of miniaturized device success backed up with empirical and scientifically analyzed data. An understanding of component and automated assembly stack-up tolerances for each component is a baseline of success but not enough. Each component must be scrutinized and “process mapped on steroids” to prevent late and very costly development and clinical trial failures.



The Advanced Manufacturing Technology Series Asia • North America • South America Learn More »